Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: Medday's MD1003 meets Phase III endpoint in MS

    Medday S.A.S. (Paris, France) said MD1003 met the primary endpoint of disease improvement in a Phase III trial to treat multiple sclerosis (MS). The primary endpoint was defined as the proportion of patients who showed …

    Published on 4/17/2015
  • CLINICAL NEWS: Momenta reports equivalence data for generic Copaxone

    Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said data demonstrate equivalence between its once-daily Glatopa glatiramer acetate and blockbuster multiple sclerosis (MS) drug Copaxone from Teva Pharmaceutical Industries …

    Published on 4/17/2015
  • CLINICAL NEWS: Opdivo meets OS endpoint in non-squamous NSCLC study

    Bristol-Myers Squibb Co. (NYSE:BMY) stopped the Phase III CheckMate -057 trial early after an independent data monitoring committee concluded that Opdivo nivolumab met the primary endpoint of superiority to docetaxel in…

    Published on 4/17/2015
  • CLINICAL NEWS: RG7800 shows proof of mechanism in Phase I

    An abstract released ahead of the American Academy of Neurology meeting said RG7800 from Roche (SIX:ROG; OTCQX:RHHBY) demonstrated proof of mechanism in a Phase I trial by showing a dose-dependent effect on splicing of …

    Published on 4/17/2015
  • CLINICAL NEWS: Active Biotech, Ipsen discontinue tasquinimod in mCRPC

    Active Biotech AB (SSE:ACTI) plummeted SEK16.80 (61%) to SEK10.90 after the company and partner Ipsen Group (Euronext:IPN) said they would discontinue development of tasquinimod to treat prostate cancer. Tasquinimod …

    Published on 4/16/2015
  • CLINICAL NEWS: Alzheimer's Association to evaluate clinical utility of amyloid imaging

    The Alzheimer's Association launched a four-year study to evaluate the clinical utility and health outcomes associated with using positron emission tomography (PET) of amyloid deposits in the brain to help diagnose …

    Published on 4/16/2015
  • CLINICAL NEWS: AnaptysBio plans study of first-in-class IL-36R antagonist

    Antibody platform company AnaptysBio Inc. (San Diego, Calif.) began IND-enabling studies of first-in-class IL-36R antagonist ANB019 to treat generalized pustular psoriasis (GPP), a rare but life-threatening inherited …

    Published on 4/16/2015
  • CLINICAL NEWS: Receptos' ozanimod meets maintenance endpoints in UC

    Receptos Inc. (NASDAQ:RCPT) gained $9.65 to $167.97 on Thursday after it said 1 mg doses of ozanimod (RPC1063) met all primary and secondary efficacy endpoints in the maintenance portion of the Phase II TOUCHSTONE trial…

    Published on 4/16/2015
  • CLINICAL NEWS: Studies identify room for improvement in tumor genome analysis

    Two studies published Wednesday in Science Translational Medicine suggest precision medicine based on sequencing of tumor genomes could benefit from deeper analyses to confirm which mutations are actionable drivers of …

    Published on 4/15/2015
  • CLINICAL NEWS: Biogen reports more data for anti-LINGO mAb in optic neuritis

    Biogen Inc. (NASDAQ:BIIB) reported new data from the Phase II RENEW study of BIIB033 to treat acute optic neuritis, showing that patients receiving the compound had "continuous improvement" for 12 weeks after receiving …

    Published on 4/14/2015
  • CLINICAL NEWS: GW's Epidiolex reduces seizures in expanded access study

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) gained $12.57 (13%) to $108.75 on NASDAQ and 27.5p to 587p in London on Tuesday after data were published from an open-label study of Epidiolex cannabidiol in treatment-…

    Published on 4/14/2015
  • CLINICAL NEWS: Pharmalink's Nefecon meets nephropathy endpoint

    Pharmalink AB (Stockholm, Sweden) stopped the Phase IIb NEFIGAN trial early after an interim analysis showed Nefecon (PL-56) met the primary endpoint to treat IgA nephropathy.Daily administration of Nefecon led to …

    Published on 4/14/2015
  • CLINICAL NEWS: Sihuan begins U.S. pirotinib trial

    Sihuan Pharmaceutical Holdings Group Ltd. (HKSE:0460) said its Shandong XuanZhu Pharma Co. Ltd. subsidiary began a U.S. Phase I trial of pirotinib (KBP5209) to treat advanced solid tumors including non-small cell lung, …

    Published on 4/13/2015
  • CLINICAL NEWS: GlycoMimetics: Pfizer will start delayed rivipansel trial

    GlycoMimetics Inc. (NASDAQ:GLYC) said partner Pfizer Inc. (NYSE:PFE) will begin a Phase III trial in mid-2015 of rivipansel (GMI-1070) to treat vaso-occlusive crisis (VOC) in patients with sickle cell disease. Pfizer …

    Published on 4/7/2015
  • CLINICAL NEWS: Ocular's OTX-DP misses in Phase III study

    Ocular Therapeutix Inc. (NASDAQ:OCUL) lost $12.98 (34%) to $25.32 in early after-hours trading on Monday after its dexamethasone-loaded punctum plug (OTX-DP) missed one of two primary efficacy endpoints in the second of…

    Published on 4/6/2015
  • CLINICAL NEWS: NEJM publishes Ebola vaccine data

    Single doses of Ebola vaccine RVSV-EBOV (VSV-ZEBOV; VSV-EBOV) led to an immune response in multiple Phase I trials conducted in the U.S., Switzerland, Germany, Gabon and Kenya. No serious vaccine-related adverse events …

    Published on 4/2/2015
  • CLINICAL NEWS: Dyax market cap tops $3.5B on DX-2930 news

    Dyax Corp. (NASDAQ:DYAX) gained $9 (54%) to $25.75 on Wednesday following postmarket data Tuesday that showed DX-2930 significantly reduced hereditary angioedema (HAE) attacks in a Phase Ib trial and received Fast Track…

    Published on 4/1/2015
  • CLINICAL NEWS: Dyax surges on DX-2930 news

    Dyax Corp. (NASDAQ:DYAX) jumped $8.40 (50%) to $25.15 in early after-hours trading on Tuesday on postmarket news that its DX-2930 significantly reduced hereditary angioedema (HAE) attacks in a Phase Ib trial. The …

    Published on 3/31/2015
  • CLINICAL NEWS: BioDelivery falls on Phase III miss

    BioDelivery Sciences International Inc. (NASDAQ:BDSI) shed $3.38 (24%) to $10.51 on Monday after its clonidine topical gel (ARC-4558) missed the primary endpoint in a Phase III trial to treat painful diabetic neuropathy…

    Published on 3/30/2015
  • CLINICAL NEWS: Chi-Med's fruquintinib meets in mCRC Phase II

    Hutchison China MediTech Ltd. (LSE:HCM) said fruquintinib (HMPL-013) met the primary endpoint of progression-free survival (PFS) in a Chinese Phase II study to treat metastatic colorectal cancer (mCRC). Chi-Med said its…

    Published on 3/30/2015
  • CLINICAL NEWS: Genfit sinks on Phase II NASH data

    Genfit S.A. (Euronext:GNFT) plunged EUR 22.54 (44%) to a six-month low of EUR 28.31 on Friday after its GFT505 missed the primary endpoint in the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH)…

    Published on 3/27/2015
  • CLINICAL NEWS: Northwest gains on GBM survival data

    Northwest Biotherapeutics Inc. (NASDAQ:NWBO) reported data from glioblastoma multiforme (GBM) patients who were ineligible for enrollment in the company's ongoing Phase III trial of DCVax-Brain (DCVax-L), and instead …

    Published on 3/27/2015
  • CLINICAL NEWS: Conatus' emricasan meets Phase II endpoint

    Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) jumped $1 (17%) to $6.76 on Thursday after it said pan-caspase inhibitor emricasan met the primary endpoint of a Phase II trial to treat non-alcoholic fatty liver disease (…

    Published on 3/26/2015
  • CLINICAL NEWS: Genfit reports Phase II NASH data

    Genfit S.A. (Euronext:GNFT) said GFT505 missed the primary endpoint of the Phase IIb GOLDEN-505 trial to treat non-alcoholic steatohepatitis (NASH) according to the study's initial design. GFT505 met the endpoint after …

    Published on 3/26/2015
  • CLINICAL NEWS: VBL gains on Phase II GBM data

    VBL Therapeutics Ltd. (NASDAQ:VBLT) gained $1.63 (29%) to $7.22 on Wednesday after VB-111 met the primary endpoint of improving overall survival (OS) in a Phase II trial to treat recurrent glioblastoma multiforme (GBM).…

    Published on 3/25/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993